AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
World game at war: why some European nations have threatened a World Cup boycott 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
SAN DIEGO, April 17, 2018 -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report first quarter 2018 financial results on Tuesday, May 1, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
| Conference Call Information | ||
| Date: | Tuesday, May 1, 2018 | |
| Time: | 4:30 p.m. ET | |
| Dial-in numbers: | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) | |
| Confirmation code: | 1169697 | |
| Live webcast: | Retrophin.com in the “Events & Presentations” section of the “Investors” page | |
A replay of the call will be available from 7:30 p.m. ET, May 1, 2018 to 7:30 p.m. ET, May 8, 2018. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 1169697.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare diseases. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam® and Thiola®.
Contact:
Chris Cline, CFA
Vice President, Investor Relations & Corporate Communications
646-564-3680
[email protected]
